NEU neuren pharmaceuticals limited

Ann: Validation for NNZ-2591 neurodevelopmental disorder pipeline, page-89

  1. 1,639 Posts.
    lightbulb Created with Sketch. 371
    We obviously will never be told but it would be great to know what value the Board are placing on the ROW rights and also the full sale of the business. Id imagine these would have been detailed to Torreya who are tasked with sourcing a deal. Would be fantastic to know what feedback they have received thus far given its almost been 4 months since they have been appointed. The Pitt St commissioned research didn't place any value on NNZ-2591 and provided a $4.17 lower end value. Would $5-6 for the whole business be agreeable to the Board? Who knows.
    As HT detailed the regulatory package for the rights outside of NA has considerable value. I struggle to see there being no interest in the ROW rights, its just a matter of finding the agreeable number and terms.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$13.10
Change
-0.800(5.76%)
Mkt cap ! $1.629B
Open High Low Value Volume
$13.95 $13.96 $12.88 $9.534M 725.6K

Buyers (Bids)

No. Vol. Price($)
1 266 $13.10
 

Sellers (Offers)

Price($) Vol. No.
$13.15 1619 2
View Market Depth
Last trade - 16.10pm 13/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.